Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Preclinical assessment of combination therapy of EGFR tyrosine kinase inhibitors in a highly heterogeneous tumor model.

Oncogene - 1 Apr 2022

Ikeuchi Hiroshi, Hirose Takeshi, Ikegami Masachika, Takamochi Kazuya, Suzuki Kenji, Mano Hiroyuki, Kohsaka Shinji

Abstract excerpt

The development of tyrosine kinase inhibitors (TKIs) has improved the treatment of non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations. The current research priority is to provide viable treatments for patients who have drug-resistant EGFR mutations. We evaluated the drug sensitivity of various EGFR mutants to monotherapies and combination therapies of EGFR-TKIs. In vitro,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Afatinib
Share to Aniline Compounds

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Models, Theoretical

Share to Protein Kinase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 35304574
DOI: 10.1038/s41388-022-02263-4
PMCID: PMC9033582

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Preclinical assessment of combination therapy of EGFR tyrosine kinase inhibitors in a highly heterogeneous tumor model.PMID 35304574Read ↗

Allele-dependent variation in the relative cellular potency of distinct EGFR inhibitors.Semantic proximity Read ↗

Efficacy of Novel Third-Generation Tyrosine Kinase Inhibitors for Uncommon <em>EGFR</em> Mutations – an In Vitro StudySemantic proximity Read ↗

Comparing the Efficacy of Two Generations of EGFR-TKIs: An Integrated Drug-Disease Mechanistic Model Approach in Egfr-Mutant Lung AdenocarcinomaSemantic proximity Read ↗

Construction of a novel cell-based assay for the evaluation of anti-EGFR drug efficacy against EGFR mutation.Semantic proximity Read ↗

A novel strategy of EGFR‑TKI combined chemotherapy in the treatment of human lung cancer with EGFR‑sensitive mutation.Semantic proximity Read ↗

Utility of the Ba/F3 cell system for exploring on-target mechanisms of resistance to targeted therapies for lung cancer.Semantic proximity Read ↗

Clinical and Preclinical Activity of EGFR Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer Harboring BRAF Class 3 Mutations.Semantic proximity Read ↗

Upfront admixing antibodies and EGFR inhibitors preempts sequential treatments in lung cancer models.Semantic proximity Read ↗

Afatinib plus PEM and CBDCA overcome osimertinib resistance in EGFR-mutated NSCLC with high thrombospondin-1 expression.Semantic proximity Read ↗

Triplet therapy with afatinib, cetuximab, and bevacizumab induces deep remission in lung cancer cells harboring EGFR T790M in vivo.Semantic proximity Read ↗

Afatinib plus Cetuximab Delays Resistance Compared to Single-Agent Erlotinib or Afatinib in Mouse Models of TKI-Naïve EGFR L858R-Induced Lung Adenocarcinoma.Semantic proximity Read ↗

Afatinib prolongs survival compared with gefitinib in an epidermal growth factor receptor-driven lung cancer model.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.